How Jardiance Causes Polycythemia
Jardiance (empagliflozin) causes polycythemia through two primary mechanisms: hemoconcentration from intravascular volume contraction due to osmotic diuresis, and stimulation of erythropoietin (EPO) production leading to true erythrocytosis.
Dual Mechanism of Action
Volume Contraction (Hemoconcentration)
The FDA label explicitly states that JARDIANCE causes intravascular volume contraction 1. As an SGLT2 inhibitor, empagliflozin blocks glucose reabsorption in the proximal tubule, causing:
- Osmotic diuresis with elimination of 60-100 g of glucose daily 2
- Plasma volume reduction
- Relative concentration of red blood cells (hemoconcentration)
- This mechanism can unmask underlying polycythemia vera, as documented in case reports 3
True Erythropoiesis Stimulation
Beyond simple hemoconcentration, SGLT2 inhibitors actively stimulate red blood cell production 4, 5:
- Enhanced EPO secretion from the kidneys
- Improved renal tubular oxygenation and metabolism 2
- Direct erythropoietic effects independent of volume status
- This explains why hemoglobin increases persist even after initial volume changes stabilize
Clinical Magnitude and Time Course
Meta-analysis data demonstrate consistent hematologic changes 4:
- Hematocrit increases by +2.29% (95% CI 1.48 to 3.09)
- Hemoglobin increases by +0.51 g/dL (95% CI 0.28 to 0.74)
- Changes occur early after treatment initiation
- Real-world prevalence of polycythemia increased from 2.4% to 9.7%, with severe cases in 1.4% of patients 4
The trajectory is typically transient and self-limiting 6:
- Erythrocytosis prevalence peaks at 8.0% at 6 months
- Returns toward baseline (5.9%) by 12 months
- Hemoglobin levels often normalize within two years even with continued therapy 7
Risk Factors for Developing Polycythemia
Independent predictors of SGLT2i-induced erythrocytosis include 6:
- Higher baseline hemoglobin (dominant predictor)
- Male sex
- Higher medication adherence
- Current smoking
- COPD or asthma
- Higher heart rate
- Lower serum albumin
- Dyslipidemia and hyperuricemia 7
Clinical Significance and Safety
The polycythemia appears clinically benign in most cases:
- No association with mortality, MACE, or thrombotic events in the largest prospective registry (1,244 patients) 6
- Two-year cardio-renal outcomes unaffected in IgA nephropathy patients who developed polycythemia 7
- One observational study (100 patients with JAK2-unmutated erythrocytosis) reported 10% thrombotic event rate, but causality unclear 4
However, the FDA label does not specifically warn about polycythemia, focusing instead on volume depletion risks 1. The hematologic changes may actually contribute to cardiovascular benefit through improved oxygen delivery 6.
Practical Management Approach
Monitor but do not routinely discontinue:
- Check baseline hemoglobin/hematocrit before initiating therapy
- Recheck at 3-6 months, then periodically
- Continue SGLT2i therapy even if polycythemia develops, as it is typically transient and not associated with adverse outcomes 7, 6
- Consider discontinuation only if:
- Severe erythrocytosis develops (hematocrit >54% in men, >48% in women)
- Patient has underlying myeloproliferative disorder
- Thrombotic events occur
The effect is reversible: Discontinuation leads to normalization of hematologic parameters 4, 3, though this should be reserved for clinically significant cases given the substantial cardiovascular and renal benefits of SGLT2i therapy 8, 2.
Key caveat: Patients with baseline high hemoglobin can still develop further increases 7, and the drug may unmask underlying polycythemia vera 3. Screen for JAK2 mutations if polycythemia is accompanied by leukocytosis or thrombocytosis 9.